We scan new podcasts and send you the top 5 insights daily.
Early CFD adoption in biotech faltered because limited compute power forced engineers to use geometric simplifications, such as simulating a single periodic cake slice instead of the entire reactor cylinder. Bioreactors contain massive three-dimensional wrapping flows that cannot be captured in periodic wedge models. These simplifications produced inaccurate results, leading teams to experience poor outcomes and abandon simulation for years.
Scaling up a bioprocess from lab to production fundamentally alters physical properties like oxygen transfer (KLA). This change in physics, not necessarily a procedural mistake, is often the root cause of failure at scale, leading to different cell growth and product quality.
Christian Witz notes that biotech scientists frequently treat CFD as an intimidating tool requiring a dedicated physics or mathematics PhD. However, the real obstacle is that conventional CFD user interfaces have not been tailored to bioprocess workflows. Just as modern computer use does not require an IT technician, tailored interfaces allow routine process development scientists to employ CFD daily like Excel.
Because CFD operates strictly on physical parameters rather than biological mechanisms, a vessel needs to be fully characterized only once across 100 to 200 operational points. When switching to a new molecule, media, or cell line, the scale-up software only needs updated fluid properties such as viscosity, density, surface tension, and salt concentration, eliminating the need to re-run simulations from scratch.
By training on multi-scale data from lab, pilot, and production runs, AI can predict how parameters like mixing and oxygen transfer will change at larger volumes. This enables teams to proactively adjust processes, moving from 'hoping' a process scales to 'knowing' it will.
Characterizing a bioreactor requires careful boundary setting because every additional variable exponentially increases the required simulation count. Adding wide continuum ranges for parameters like working volume or fluid viscosities creates an enormous operational space. Teams must strategically limit variables to discrete, sensible operating increments rather than attempting to model extreme spectrums from empty vessels to honey-like viscosities.
The most significant breakthroughs will no longer come from traditional wet lab experiments alone. Instead, progress will be driven by the smarter application of AI and simulations, with future bioreactors being as much digital as they are physical.
Scaling from a T-flask to a bioreactor isn't just increasing volume; it's a fundamental shift in the biological context. Changes in cell density, mass transfer, and mechanical stress rewire cell signaling. Therefore, understanding and respecting the cell's biology must be the primary design input for successful scale-up.
The future of bioprocess development involves using AI on high-throughput data for predictive modeling. This, combined with in silico simulations (digital twins), will allow scientists to understand underlying biological mechanisms, not just identify optimal conditions, dramatically accelerating optimization.
The challenge of scaling 3D cell cultures isn't just about building larger systems. A more fundamental problem is the inability to measure and characterize the complex 3D environment in real-time. Without effective in-process analytics to ensure quality control and process optimization, true industrial scalability remains unachievable.
Conventional cell line development screens clones in small-scale formats like 96-well plates. This environment starkly differs from the large-scale, controlled bioreactors used in production, leading to clones that perform well initially but fail when scaled up, creating a costly and predictable development bottleneck.